Core Viewpoint - The company has decided to terminate the "Data Science Center Project" and permanently supplement the remaining raised funds into working capital due to changes in market conditions and its operational strategy [4][6][8]. Fundraising Overview - The company raised a total of RMB 1,183.2 million from its initial public offering, with a net amount of RMB 1,087.6 million after deducting issuance costs [1]. - As of April 30, 2025, the company has used RMB 578.5 million of the raised funds, leaving a balance of RMB 558.9 million [2]. Investment Project Status - The total investment for committed projects is RMB 610 million, with RMB 298.5 million already invested [2]. - The company has also allocated RMB 477.6 million for projects funded by excess raised funds, with RMB 280 million already utilized [2]. Termination of Investment Projects - The "Data Science Center Project" was intended to enhance the company's data management and statistical analysis capabilities but has been terminated due to macroeconomic factors and market demand changes [5][6]. - The remaining funds from this project, amounting to RMB 177.7 million, will be permanently added to working capital [6]. Impact on Daily Operations - The termination of the project is expected to have no adverse effects on the company's existing operations and is seen as a strategic decision to optimize fund usage [6][8]. - The decision aligns with the company's goal to improve the efficiency of fund utilization and meet daily operational funding needs [6][8]. Approval Process - The board of directors has approved the termination of the project and the reallocation of funds, which will be submitted for shareholder approval [7][8]. Sponsor's Review Opinion - The sponsor believes that the decision to terminate the project and reallocate funds is in line with the company's operational needs and will enhance the economic benefits of the raised funds [8][9].

证券代码：301333 证券简称：诺思格 公告编号：2025-027 诺思格（北京）医药科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完 经审议，监事会认为：本次终止数据科学中心项目是公司结合实际情况和中 长期发展规划而做出的审慎决策，有利于提高募集资金使用效率，符合公司和股 东利益，不存在违反中国证监会、深圳证券交易所关于上市公司募集资金使用的 有关规定的情形，同意终止数据科学中心项目并将该项目剩余募集资金永久补充 流动资金。 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第四届监事会 第八次会议于2025年6月5日在公司会议室以现场结合通讯方式召开。会议通知已 于2025年5月28日以电子邮件、专人送达等方式送达全体监事。本次会议应出席 监事3人，实际出席监事3人。会议由监事会主席关虹主持。会议召开符合有关法 律、法规、规章和《诺思格（北京）医药科技股份有限公司章程》 （以下简称《公 司章程》）的规定。 二、监事会会议审议情况 （一）审议通过《关于终止部分募投项目并将剩余募集资金永久补充流动资 金的议案》 表 ...

南京生物医药分中心副主任吴昊介绍，分中心建立了84亿元规模的全生命周期资金支持体系，包括财政 资金、天使基金、政府性融资担保、银行信贷等，并且还打造了一支140余人的专兼职技术经理人队 伍，为高校团队提供全方位、一站式的支持，助力项目快速落地生根、茁壮成长。 未来，南京生物医药分中心将持续发挥科技中介作用，进一步加强与高校、企业的深度合作，助力生物 医药产业实现高质量发展。 去年下半年，王亚峰和团队开始考虑将相关研究成果转化并创办企业。在与分中心对接后，王亚峰带着 成果注册了英诺思(南京)生物科技有限责任公司。"从高校到落地在南京生物医药分中心，不过一两个 月，我们就组建好了10人团队"。眼下，英诺思团队一边为客户提供免疫细胞分离及功能检测等科技服 务，一边进行一款免疫分析试剂盒的自主研发。短短几个月时间，"书架"上的成果已经成功"下线"，企 业研发的多款免疫试剂盒产品正式走入市场。 本报讯(钱钰玲)去年9月，教育部和我省签署协议，共建首个全国高校区域技术转移转化中心，南京生 物医药分中心落户江北新区南京生物医药谷。启动建设半年多来，该中心已接洽全国高校68家，遴选医 药成果1123项，入驻项目31个，吸引了 ...